Long-term safety of belzutifan in von Hippel-Lindau syndrome: A single-center experience. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full ...
Use of an RNA-based HRD signature significantly expands the fraction of patients with prostate cancer who may derive benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) compared with using ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback